[Macugen 2 year systemic safety data is clean]
from Briefing.com:
>>8:10AM OSI Pharm: Systemic safety profile of Macugen maintained throughout two years with no increased risk of Cardiovascular events (OSIP) 31.27 : OSIP and Pfizer (PFE) announced today that the systemic safety profile of Macugen, already established in data from Year 1 of the VISION trials, was maintained over 2 years of treatment with no evidence of an association with hypertension, serious hemorrhagic events, or thromboembolic events as compared to the control group. Such events have been noted with the clinical use of other V.E.G.F. inhibitors. Furthermore, a preliminary analysis of a third year of data suggests that the safety of Macugen is maintained throughout three years of treatment. These data were presented at the annual Macula Society meeting on February 22-25, 2006 in Carlsbad, California. The systemic safety profile of Macugen established in Year 1 was sustained in Year 2, with no evidence that Macugen was associated with an increased incidence of adverse events, such as systemic hypertension, serious hemorrhagic events, or thromboembolic events compared to the control group. Such events have been noted with the clinical use of other V.E.G.F. inhibitors. <<
To finish the lsat sentence: "but not ones injected into the eye." Lucentis hasn't had any such AEs, either, though its track record is shorter at the moment. A brokerage house upgraded OSI yesterday, saying the fallout from the Eyetech buy was priced in now. Where were they when the stock was $22?
Cheers, Tuck |
